NDAOPHTHALMICSUSPENSION/DROPS
Approved
Oct 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
7/8 — Comprehensive
EYSUVIS (loteprednol etabonate) by Alcon is healing. Approved for ocular inflammation, inflammation, pain and 4 more indications. First approved in 2020.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EYSUVIS (loteprednol etabonate) is an ophthalmic corticosteroid suspension approved by the FDA in October 2020 for treating steroid-responsive inflammatory conditions of the eye, including acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and post-operative inflammation. The drug works by inhibiting prostaglandin production and suppressing multiple inflammatory pathways including edema, fibrin deposition, capillary dilation, and leukocyte migration. EYSUVIS represents Alcon's entry into a mature ophthalmic corticosteroid market dominated by older, established agents.
$0.0BPart D
7.0 years to LOEMechanism of Action
healing. Corticosteroids inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the…
Indications (7)
Worked on EYSUVIS at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.